U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. User Fee Reports
  6. User Fee Performance Reports
  7. AGDUFA Performance Reports
  1. User Fee Reports

AGDUFA Performance Reports

AGDUFA Performance Reports

On June 13, 2013, the first reauthorization of the Animal Generic Drug User Fee Act (AGDUFA II) was signed into law. AGDUFA II amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) by reauthorizing AGDUFA for an additional 5 years (FY 2014 through FY 2018). AGDUFA provides FDA with revenue to enhance the performance and predictability in review times for the animal generic drug industry and provide FDA with resources to improve its review that result in safe and effective new products will be more readily available. AGDUFA follows the Animal Drug User Fee Act (ADUFA) model and is also similar to the Prescription Drug User Fee Act (PDUFA) program. This ensures the timely and thorough review for abbreviated new animal drug applications (ANADAs) and generic investigational new animal drug (JINAD) submissions. AGDUFA enables FDA to ensure that generic new animal drug products are provided to consumers as a safe, lower cost alternative to pioneer drugs.

AGDUFA I and AGDUFA II

  • AGDUFA I (FY 2009 to FY 2013) ADUFA I was signed into law on August 14, 2008.  AGDUFA I established review performance goals for FDA, phased in over a 5-year period.  The AGDUFA I performance goals lead to progressive, yearly performance improvements, with the on-time goal for review and action on submissions getting shorter each fiscal year. By the final year of AGDUFA I, FDA agreed to review and act on 90 percent of the submissions within the specified time 
  • AGDUFA II (FY 2014 to 2018) Under AGDUFA II (FY 2014 to 2018), FDA committed to a variety of process improvements to enhance and further improve the review process.  This now includes the ability for industry to supply two-phased data submissions as part of the Chemistry Manufacturing and Controls (CMC) Technical Section.  Also, industry can submit comparability protocols without substantial data in a JINAD file.  The Agency is now developing and implementing a new, question-based review (QbR) process for bioequivalence submissions.

Annual performance reports are prepared by the Office of Planning in collaboration with FDA’s Center for Veterinary Medicine (CVM).

For additional information on these reports, please contact:

Office of Planning
Food and Drug Administration
10903 New Hampshire Avenue
Building 32, Room 4223
Silver Spring, Maryland 20903-0002
Phone: 301-796-4850
FAX: 301-847-3541

AGDUFA Performance Reports

Performance reports for previous years are available in the FDA Archive.